| Galimberti, Sara |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi |
|
|
| Recruiting | 3 | 190 | Europe | Radiotherapy, Radiotherapy plus Obinutuzumab | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Follicular Lymphoma | 04/31 | 04/31 | | |
| Recruiting | 2 | 94 | Europe, Canada | RVU120, SEL120 | Ryvu Therapeutics SA | Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome | 02/26 | 09/26 | | |
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma |
|
|
| Withdrawn | 2 | 150 | Europe | R-DHAP, Pola-R-DHAP | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | 01/29 | 01/29 | | |
TFR-PRO, NCT04621851: Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation |
|
|
| Recruiting | N/A | 3000 | Europe, Canada | | University of Milano Bicocca | Chronic Myeloid Leukemia | 09/21 | 09/23 | | |
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) |
|
|
| Recruiting | N/A | 319 | Europe | Ropeginterferon alfa-2b, Besremi | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | Polycythemia Vera | 09/26 | 12/26 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors |
|
|
| Recruiting | N/A | 148 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Myeloid Leukemia, Pregnancy | 12/22 | 12/22 | | |
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy |
|
|
| Recruiting | N/A | 321 | Europe | Venetoclax | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia | 01/23 | 10/25 | | |
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience |
|
|
| Recruiting | N/A | 43 | Europe | | Fondazione Italiana Linfomi - ETS | Primary Cardiac Lymphoma | 04/26 | 06/26 | | |
| Recruiting | N/A | 100 | Europe | Therapeutic drug monitoring, Molecular Response | University of Pisa | Chronic Myeloid Leukemia, Chronic Phase | 01/24 | 12/24 | | |
NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms |
|
|
| Recruiting | N/A | 237 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes | 03/25 | 03/25 | | |
TIKlet, NCT01860456: TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The Study |
|
|
| Recruiting | N/A | 412 | Europe | Imatinib/Nilotinib, Gleevec, Tasigna | University of Pisa | Chronic Myeloid Leukemia | 12/24 | 12/24 | | |
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors |
|
|
| Recruiting | N/A | 552 | Europe | Lifestyles Implemented-Survivorship Care Plan (LS-SCP) | Fondazione Italiana Linfomi - ETS | Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | 02/26 | 02/26 | | |
